EU/3/18/2004

About

On 21 March 2018, orphan designation (EU/3/18/2004) was granted by the European Commission to Quintiles Ireland Limited, Ireland, for tazemetostat for the treatment of diffuse large B-cell lymphoma.

In May 2018, Quintiles Ireland Limited changed name to IQVIA RDS Ireland Limited.

Key facts

Active substance
Tazemetostat
Disease / condition
Treatment of diffuse large B-cell lymphoma
Date of decision
21/03/2018
Outcome
Positive
Orphan decision number
EU/3/18/2004

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

IQVIA RDS Ireland Limited
Estuary House
East Point Business Park
Fairview
Dublin 3
Ireland
Tel. +353 1 819 51 00
E-mail: irina.mikhailenko@iqvia.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating